Correct that 4DS own all of the patents or IP but that does not define a product. 4DS with 32 IP's is not worth a cent and would be very hard to sell individually but packaged in a fully working module holds great value.
WBT with our own and shared IP's is now worth whole lot more now that we have a working product. Although our cousins bang on that they own the IP we have to remember that we have full rights to our shared IP's and that Leti get paid for that, When you look at the overall cost of payments versus the income derived from the products that cost is minimal.
Once 4DS IF or when it is sold is the end of any income for the shareholders (myself included). If you look at WBT in around two years time we start receiving dividend twice a year. Small at first but as income increases and the SP and Value increases so does the dividends. We win in both directions of dividends and higher SP (if and when you decide to sell).
It is also possible that 4DS maybe sold and then shelved if it poses a threat to another technology.
Just my thoughts
- Forums
- ASX - By Stock
- WBT
- Ann: Weebit signs first commercial deal with US-based SkyWater
Ann: Weebit signs first commercial deal with US-based SkyWater, page-463
-
- There are more pages in this discussion • 236 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WBT (ASX) to my watchlist
|
|||||
Last
$2.53 |
Change
0.020(0.80%) |
Mkt cap ! $474.1M |
Open | High | Low | Value | Volume |
$2.51 | $2.53 | $2.51 | $47.77K | 18.96K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 1098 | $2.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.54 | 5168 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 974 | 2.630 |
1 | 1824 | 2.540 |
1 | 1 | 2.520 |
5 | 9159 | 2.510 |
11 | 24917 | 2.500 |
Price($) | Vol. | No. |
---|---|---|
2.440 | 75 | 1 |
2.450 | 113 | 1 |
2.490 | 515 | 1 |
2.510 | 2215 | 2 |
2.550 | 16082 | 4 |
Last trade - 10.10am 16/07/2024 (20 minute delay) ? |
Featured News
WBT (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online